Navigation Links
Response Genetics Reports Third Quarter 2007 Financial Results

LOS ANGELES, Nov. 14 /PRNewswire-FirstCall/ -- Response Genetics, Inc. (Nasdaq: RGDX) a company focused on the development of molecular diagnostic tests for cancer, today announced its consolidated financial results for the third quarter of 2007, and nine months ended September 30, 2007.

"The third quarter of 2007 brought new interest in Response Genetics from the physician and investment communities," said Kathleen Danenberg, President and CEO of Response Genetics. "The combination of the recent announcement of our plans to make the ERCC-1 gene expression test available in the first quarter of 2008, and the positive Journal of Clinical Oncology article in July related to the test was met with great enthusiasm from physicians, potential partners and investors. We understand the value our ERCC-1 test provides to physicians seeking to personalize disease management and improve patient outcomes, and we are excited to share it with selected institutions and clinical practice groups early next year. We look forward to providing you with further updates as events materialize."

Financial Results for Three Months Ended September 30, 2007

Total revenue increased 24% to $2.2 million in the third quarter of 2007, compared to $1.8 million in the third quarter of 2006. This increase was generated by the Company's existing pharmaceutical contracts related to pharmacogenomic testing services, and the introduction of new testing services being offered by Response Genetics to its pharmaceutical clients.

Cost of revenue for the third quarter of 2007 was $910,090, compared with $643,772 for the third quarter of 2006. Research and development expenses were $651,536 for the third quarter of 2007, compared with $267,095 for the same period in the prior year. General and administrative expenses of $1.8 million for the third quarter of 2007 increased from $656,997 for the third quarter of the prior year. Total operating expenses for the third quarter of 2007 increased to $3.3 million, compared with $1.6 million for the same period last year. The increases in operating expenses were primarily due to 1) non-cash, stock-based compensation to employees and new personnel to support the Company's growth totaled approximately $582,000, 2) operating costs related to the continuing operation of the European laboratory totaled approximately $460,000, 3) costs involving the new testing services the Company is offering, maintaining the Company's intellectual property portfolio, costs related to the completion of the Company's IPO, and costs associated with being a public company totaled approximately $729,000.

Response Genetics' net loss for the third quarter of 2007 of $898,986 or $0.09 per share, compared with a net profit of $32,382, or $0.01 per share, for the third quarter of 2006.

Financial Results for Nine Months Ended September 30, 2007

Revenues for the first nine months of 2007 increased 40% to $5.4 million, compared with $3.8 million for the first nine months of 2006. Cost of revenue for the first nine months of 2007 was $2.9 million, compared with $1.6 million reported for the first nine months of 2006. General and administrative expenses for the first nine months of the year were $5.0 million, compared to $2.2 million for the comparable period in 2006. Research and development expenses in the first nine months of 2007 totaled $1.9 million, compared to $862,797 for the comparable period in 2006. Total operating expenses for the first nine months of 2007 were $9.8 million, versus $4.7 million for the comparable period in 2006. Response Genetics reported a net loss for the nine months ended September 30, 2007 of $4.6 million, or $0.78 per share, versus a net loss for the comparable period in 2006 of $1.4, or $0.50 per share.

Cash and Cash Equivalents

Cash and cash equivalents at September 30, 2007 were $17.9 million compared to $3.0 million at September 30, 2006.

Clinical Development Highlights

Response Genetics To Make ERCC-1 Molecular Diagnostic Test Available in Q1 2008

On November 1, Response Genetics announced that it plans to make its test for Excision-Repair Cross-Complementing 1 (ERCC-1) gene expression for platin-based chemotherapy resistance available to selected institutions and clinical practice groups in the first quarter of 2008. The test will be offered only through Response Genetics' CLIA-certified laboratory in California. The initial launch will provide additional information about the clinical utility of ERCC-1 in the treatment of Non-Small Cell Lung Cancer (NSCLC); clinical practice activities such as sample acquisition, logistics, patient and physician communication; and the use of the test in normal clinical practice related to NSCLC. The Company plans to provide the appropriate financial resources to ensure that the initial market introduction is a success.

Previously, the Company announced the publication of promising results from a prospective study published in the July 1 issue of the Journal of Clinical Oncology. The data indicated that high expression of ERCC-1 in patients with advanced NSCLC predicts resistance to platin-based chemotherapy. These findings suggest that the measurement of ERCC-1 levels would play a role in individualizing treatment therapies for certain lung cancer patients. The multi-center, randomized study was designed to determine the overall response rate (complete plus partial responses) of patients with stage IIIb or IV NSCLC to cisplatin-based therapy by determining levels of the biomarker ERCC-1 mRNA in a paraffin-embedded tissue biopsy before administering treatment. The Company believes that this is the first prospective study using a biomarker to predict chemotherapy response in lung cancer.

Response Genetics, Inc. will continue research efforts in other cancers where platin-based chemotherapy is used, including colon, ovarian, gastric and esophageal and plans to expand offering of the ERCC-1 molecular diagnostic test to additional institutions and additional cancers as clinical results become available.

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI") is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit

Forward Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of Response Genetics, Inc. (the "Company") related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, the ability of the Company to make its ERCC-1 molecular diagnostic test available in the first quarter of 2008, or at all, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.



As of As of

December 31, September 30,

2006 2007



Current assets

Cash and cash equivalents $ 4,930,123 $ 17,868,827

Accounts receivable 1,288,255 1,720,240

Prepaid expenses

and other current assets 837,238 442,469

Total current assets 7,055,616 20,031,536

Property and equipment, net 1,184,963 2,545,733

Other assets 19,102 19,102

Total assets $ 8,259,681 $ 22,596,371


Current liabilities

Accounts payable $ 404,008 $ 581,749

Accrued expenses 547,119 429,627

Accrued royalties 123,852 146,016

Accrued payroll, bonus

and related liabilities 595,276 195,791

Deferred revenue 1,628,325 3,910,301

Total current liabilities 3,298,580 5,263,484

Notes payable to stockholders 716,854 --

Accrued interest on notes

payable to stockholders 329,036 --

Accrued dividends 6,097,579 --

Deferred revenue,

net of current portion 3,320,000 1,603,186

Total liabilities 13,762,049 6,866,670

Commitments and contingencies

Stockholders' (deficit) equity

Series B Convertible Preferred Stock,

$0.01 par value; 1,038,048 and 0 issued

and outstanding (liquidation preference

of $9 per share, or $9,342,432 plus

accrued but unpaid dividends) at

December 31, 2006 and September 30, 2007,

respectively 10,380 --

Series A Junior Convertible Preferred Stock,

$0.01 par value; 500,000 and 0 issued and

outstanding (liquidation preference of $5

per share, or $2,500,000) at December 31,

2006 and September 30, 2007, respectively 5,000 --

Common stock, $0.01 par value; 20,000,000

and 50,000,000 shares authorized; 2,726,320

and 10,239,276 shares issued and outstanding

at December 31, 2006 and September 30, 2007,

respectively 27,263 102,393

Additional paid-in capital 9,722,273 35,048,513

Accumulated deficit (15,267,284) (19,408,635)

Accumulated other comprehensive loss -- (12,570)

Total stockholders' (deficit) equity (5,502,368) 15,729,701

Total liabilities and stockholders'

(deficit) equity $ 8,259,681 $ 22,596,371



Three Months Nine Months

Ended September 30, Ended September 30,

2006 2007 2006 2007

Revenue $1,810,800 $2,239,653 $3,817,925 $5,355,031

Operating expenses:

Cost of revenue 643,772 910,090 1,621,902 2,916,242

General and

administrative 656,997 1,777,617 2,234,382 4,965,499

Research and

development 267,095 651,536 862,797 1,888,751

Total operating

expenses 1,567,864 3,339,242 4,719,081 9,770,491

Operating income

(loss) 242,936 (1,099,589) (901,156) (4,415,460)

Other income (expense):

Interest expense (14,069) (98) (43,947) (26,854)

Interest income 37,076 216,933 112,294 325,264

Other - - 179,000 -

Income (loss) before

income taxes 265,943 (882,754) (653,809) (4,117,050)

Provision for

income taxes - 16,232 800 24,301

Net income (loss) 265,943 (898,986) (654,609) (4,141,351)

Preferred stock

dividends (233,561) - (700,684) (412,625)

Net income (loss)

attributable to

common stockholders $32,382 $(898,986) $(1,355,293) $(4,553,976)

Net income (loss)

per share - basic $0.01 $(0.09) $(0.50) $(0.78)

Net income (loss)

per share - diluted $0.01 $(0.09) $(0.50) $(0.78)


shares - basic 2,726,320 10,239,276 2,726,320 5,875,132


shares - diluted 2,726,320 10,239,276 2,726,320 5,875,132

SOURCE Response Genetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing ... December, 2015, featured apartment community: Epic. In showcasing this featured apartment community in San ... Bay Area rental market to efficiently find housing suitable to their needs by showcasing ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back ... to choose from, the possibilities are endless. Users have full control over angle of ... Pulse masking effects, users are sure to get heads to turn. , ProPanel: Pulse ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... health care in America. As people age, more care is needed, especially with ... rising, and medical professionals are being overworked. The forgotten part of this equation: ...
(Date:11/27/2015)... ... ... The print component of “Supporting Our Caregivers” is distributed ... Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an estimated ... media strategy and across a network of top news sites and partner media ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... SAN FRANCISCO , November 26, 2015 ... 1.82 billion by 2022, according to a new report by ... as Chronic Kidney Disease (CKD) which demands kidney transplantation is ... convenient and cost effective substitute for organ transplantation. --> ... 1.82 billion by 2022, according to a new report by ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the German Drugs ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
Breaking Medicine Technology: